Methionine

Phase 3Small molecule

SSt. Jude Children's Research Hospital

Methionine is one of 44 small molecule programs targeting Pulmonary Sarcoidosis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pulmonary SarcoidosisActive, not recruiting

Pulmonary Alveolar ProteinosisActive, not recruiting

MyelopathyActive, not recruiting

Pulmonary SarcoidosisPhase 2/Phase 3

Active, not recruiting

Pulmonary Alveolar ProteinosisPhase 1/Phase 2

Active, not recruiting

MyelopathyPhase 3

Active, not recruiting

Competition

Competitive Landscape

35 competitors in Pulmonary Sarcoidosis

#DrugCompanyPhaseTrials

Trexall

Alnylam Pharmaceuticals

Approved

1 2

Plaquenil

Alnylam Pharmaceuticals

Approved

1 3

Nicorette

Rayos

3 5

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 6

Myfortic

Novartis

Phase 3

1 7

Acthar

MMallinckrodt

Approved

2 8

Cellcept

Novartis

Phase 3

—9

Decadron

AAspen Global Incorporated

Phase 3

1 10

Tracleer

Johnson & Johnson

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Cancer

NCT00840047

Clinical

Trials by Indication[1]

Pulmonary Sarcoidosis1 trial

Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis

Unknown status·TTurku University Hospital·Phase 2/3·NCT02824419·10 enrolled

Myelopathy1 trial

Treatment of AIDS Vacuolar Myelopathy With Methionine

Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 3·NCT00032695·56 enrolled

Pulmonary Alveolar Proteinosis1 trial

Administration of Methionine in Patients With Pulmonary Alveolar Proteinosis by Mutation of the MARS Gene.

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 1/2·NCT03887169·3 enrolled

Cancer1 trial

Methionine PET/CT Studies In Patients With Cancer

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT00840047·503 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Methionine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Methionine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Methionine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — St. Jude Children's Research Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSt. Jude Children's Research Hospital

Methionine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Pulmonary Sarcoidosis1 trial

Myelopathy1 trial

Pulmonary Alveolar Proteinosis1 trial

Cancer1 trial

References

Drug Info

Quick Facts

Related News